Literature DB >> 16854964

Hypoxia in head and neck cancer.

A Y Isa1, T H Ward, C M L West, N J Slevin, J J Homer.   

Abstract

A high level of hypoxia in solid tumours is an adverse prognostic factor for the poor outcome of cancer patients following treatment. This review describes the status of research into finding a practical method for measuring hypoxia and treating hypoxic tumours. The application of such methodology would enable the selection of head and neck cancer treatment based on an individual's tumour oxygenation status. This individualization would include the selection not only of surgery or radiotherapy, but also of novel hypoxia-modification strategies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16854964     DOI： 10.1259/bjr/17904358

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  30 in total

1.  Increased glucose metabolism by FDG-PET correlates with reduced tumor angiogenesis in oral squamous cell carcinoma.

Authors:  Mikiko Nakamura; Yoshimasa Kitagawa; Yutaka Yamazaki; Hironobu Hata; Motoko Kotsuji; Yasuhisa Fujibayashi; Hidehiko Okazawa; Yoshiharu Yonekura; Kazuo Sano
Journal:  Odontology       Date:  2011-05-13       Impact factor: 2.634

2.  Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features.

Authors:  Mireia Crispin-Ortuzar; Aditya Apte; Milan Grkovski; Jung Hun Oh; Nancy Y Lee; Heiko Schöder; John L Humm; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2017-12-19       Impact factor: 6.280

3.  Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC).

Authors:  Nadarajah Vigneswaran; Jean Wu; Anren Song; Ananth Annapragada; Wolfgang Zacharias
Journal:  Exp Mol Pathol       Date:  2011-01-12       Impact factor: 3.362

4.  HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.

Authors:  Xin Wang; Abraham Schneider
Journal:  Carcinogenesis       Date:  2010-04-15       Impact factor: 4.944

5.  Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma.

Authors:  Abraham Schneider; Rania H Younis; J Silvio Gutkind
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

Review 6.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

7.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

8.  Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Authors:  Paul D Bonnitcha; Simon R Bayly; Mark B M Theobald; Helen M Betts; Jason S Lewis; Jonathan R Dilworth
Journal:  J Inorg Biochem       Date:  2009-10-24       Impact factor: 4.155

9.  Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Authors:  David W Dietz; Farrokh Dehdashti; Perry W Grigsby; Robert S Malyapa; Robert J Myerson; Joel Picus; Jon Ritter; Jason S Lewis; Michael J Welch; Barry A Siegel
Journal:  Dis Colon Rectum       Date:  2008-08-06       Impact factor: 4.585

10.  Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.

Authors:  Nancy Lee; Sadek Nehmeh; Heiko Schöder; Matthew Fury; Kelvin Chan; C Clifton Ling; John Humm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-07       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.